Lipocine Inc. (LPCN) Given $18.80 Average Target Price by Analysts
Shares of Lipocine Inc. (NASDAQ:LPCN) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price target of $18.80 for the company and are forecasting that the company will post ($0.31) EPS for the current quarter, according to Zacks. Zacks has also assigned Lipocine an industry rank of 85 out of 265 based on the ratings given to its competitors.
Several research analysts have recently issued reports on LPCN shares. Canaccord Genuity set a $15.00 target price on shares of Lipocine and gave the company a “buy” rating in a research note on Tuesday, December 20th. Roth Capital set a $30.00 target price on shares of Lipocine and gave the company a “buy” rating in a research note on Tuesday, December 6th. Finally, HC Wainwright initiated coverage on shares of Lipocine in a research note on Monday, October 17th. They issued a “buy” rating and a $25.00 target price for the company.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System purchased a new position in shares of Lipocine during the second quarter valued at $106,000. JPMorgan Chase & Co. purchased a new position in shares of Lipocine during the third quarter valued at $935,000. Wells Fargo & Company MN purchased a new position in shares of Lipocine during the third quarter valued at $122,000. Carlson Capital L P increased its position in shares of Lipocine by 88.3% in the second quarter. Carlson Capital L P now owns 510,000 shares of the specialty pharmaceutical company’s stock valued at $1,550,000 after buying an additional 239,170 shares during the last quarter. Finally, State Street Corp increased its position in shares of Lipocine by 1,408.9% in the second quarter. State Street Corp now owns 200,679 shares of the specialty pharmaceutical company’s stock valued at $609,000 after buying an additional 187,379 shares during the last quarter. 45.09% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Daily Political and is the propert of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this piece can be viewed at http://www.dailypolitical.com/2017/01/13/lipocine-inc-lpcn-given-18-80-average-target-price-by-analysts.html.
Shares of Lipocine (NASDAQ:LPCN) opened at 3.51 on Wednesday. The stock’s 50 day moving average is $3.66 and its 200 day moving average is $3.82. Lipocine has a 12 month low of $2.51 and a 12 month high of $12.66. The firm’s market cap is $64.09 million.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.